API | vonoprazan

vonoprazan Report issue

Small molecule Experimental

AACT DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Vonoprazan, sold under the brand name Takecab among others, is a first-in-class potassium-competitive acid blocker medication. It was approved in the Japanese market in February 2015. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine | tak438 | tak 438 | tak-438 | takecab | vonoprazan | vonoprazan fumarate

Organizations (35)

Research & Development (35)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (14)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (14)

Acute Coronary Syndrome (Phase 4)

Drugs, Investigational (Phase 1)

Duodenal Ulcer (Phase 3)

Esophagitis (Phase 4)

Esophagitis, Peptic (Phase 4)

Fasting (Phase 1)

Gastritis (Phase 4)

Gastroesophageal Reflux (Phase 4)

Healthy Volunteers (Phase 3)

Heartburn (Phase 2)

Helicobacter pylori (Phase 4)

Intestinal Neoplasms (Phase 2)

Peptic Ulcer (Phase 1)

Stomach Ulcer (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 58
# of Trial Organizations: 35

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue